Wall Street brokerages expect Ritter Pharmaceuticals Inc (NASDAQ:RTTR) to report earnings of ($0.93) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Ritter Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.09) and the highest estimate coming in at ($0.77). Ritter Pharmaceuticals posted earnings of ($1.10) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 15.5%. The firm is scheduled to announce its next quarterly earnings results on Monday, March 18th.
On average, analysts expect that Ritter Pharmaceuticals will report full-year earnings of ($2.84) per share for the current financial year, with EPS estimates ranging from ($3.05) to ($2.63). For the next financial year, analysts forecast that the company will report earnings of ($1.66) per share, with EPS estimates ranging from ($2.12) to ($1.20). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Ritter Pharmaceuticals.
Several research firms have recently issued reports on RTTR. HC Wainwright set a $15.00 price objective on Ritter Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 15th. ValuEngine upgraded Ritter Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd. Finally, Zacks Investment Research upgraded Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.00 price objective on the stock in a report on Friday, November 16th.
Shares of NASDAQ:RTTR opened at $0.89 on Friday. The firm has a market cap of $4.22 million, a price-to-earnings ratio of -0.18 and a beta of 1.21. Ritter Pharmaceuticals has a one year low of $0.71 and a one year high of $4.00.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.
Further Reading: Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.